No Data
MicroPort CardioFlow to Narrow Losses in 2024; Shares Rise 7%
CARDIOFLOW-B (02160.HK) expects a net loss in 2024 to narrow by approximately 87% year-on-year to 94%.
Glory Financial reported on March 6 that CARDIOFLOW-B (02160.HK) announced that based on the preliminary review of the group's unaudited management accounts for the year ending December 31, 2024, and the assessment of the latest information currently available to the Board of Directors, the group expects to record a net loss of approximately RMB 30 million to RMB 60 million during the reporting period, a decrease of about 87% to 94% compared to the year ending December 31, 2023. This decrease is mainly due to: 1) The company's transcatheter aortic valve implantation products Vita Flow and VitaFlow Liberty.
Express News | Microport Cardioflow Medtech - Expected Result Due to Fair Value Gains on Convertible Instruments Issued by 4C Medical in FY, Others
Express News | Microport Cardioflow Medtech Sees FY Net Loss RMB30 Mln to RMB60 Mln
CARDIOFLOW-B: PROFIT FORECAST FOR THE YEAR OF 2024 - SIGNIFICANT REDUCTION IN NET LOSS
The new drug development time is cut in half, diagnoses are more accurate, industry barriers are lowered... AI is transforming the Medical Industry in China.
On February 26, Deutsche Bank Analyst Cyrus Ng released a report stating that the entire Medical Industry in China, from drug development and diagnostics to Hospital management, will benefit from the AI revolution.
